Five things for pharma marketers to know: Thursday, September 14, 2017

Share this content:


1. More than one-third of clinical trials are never publicly registered and roughly half of trial results are published, according to a new study in JAMA. This may be done to bury results that find treatments unsafe or ineffective. (Reuters)

2. The Institute for Clinical and Economic Review revised its cost-effectiveness analysis of Amgen's cholesterol-lowering injection, Repatha, saying the drug's value-based price benchmark is between $1,725 and $2,242. Its actual list price of $14,100. (BioPharmaDive)

3. Receiving a flu shot during pregnancy may increase a woman's risk of miscarrying, according to new research published in Vaccine. (Stat)

4. A survey of 823 cancer patients found that only 40% of them could name an immunotherapy, according to the social network Inspire. Bristol-Myers Squibb's Opdivo was the most frequently named immunotherapy among those patients who could name one. (Inspire)

5. Ohio's Hamilton County plans to hand out more than 30,000 doses of an opioid-overdose reversal spray called Narcan, or one dose for every 27 residents. (Bloomberg)


Share this content:
Scroll down to see the next article